- Conditions
- Crohn's Disease
- Interventions
- Matching Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 119
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 5,346
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Heart Failure
- Interventions
- HeartWare® VAS
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • San Diego, California • Stanford, California + 29 more
- Conditions
- Epilepsy
- Interventions
- Lamotrigine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 54 more
- Conditions
- Rheumatologic Conditions (JRA,Lupus), Epilepsy, Spina Bifida, Asthma
- Interventions
- Coping Skills Training
- Behavioral
- Lead sponsor
- Children's Hospital and Health System Foundation, Wisconsin
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Steroid-Refractory Acute Graft Versus Host Disease
- Interventions
- T-Guard
- Drug
- Lead sponsor
- Xenikos
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 24
- States / cities
- Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CPX-351, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
- Conditions
- Cardiac Arrest Due to Underlying Cardiac Condition, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Interventions
- Initial CCL admission, Initial ICU admission
- Procedure · Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Ann Arbor, Michigan + 14 more
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
- Interventions
- Cytology Specimen Collection Procedure, Medical Chart Review
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 75,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 246
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Treosulfan
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
- Conditions
- Severe Aplastic Anemia
- Interventions
- Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
- Drug · Radiation · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 28
- States / cities
- Duarte, California • Los Angeles, California • Oakland, California + 24 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
- Conditions
- Cardiovascular Risk, Acute Myocardial Infarction (AMI)
- Interventions
- Ziltivekimab, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 188
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more
- Conditions
- Head and Neck Cancer
- Interventions
- biologic sample preservation procedure, biopsy
- Other · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Sacramento, California • Colorado Springs, Colorado + 68 more
- Conditions
- Anal Cancer
- Interventions
- Home-based human papillomavirus (HPV) DNA screening, Clinic-based human papillomavirus (HPV) DNA screening
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- RELiZORB, Placebo
- Device
- Lead sponsor
- Alcresta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
- Conditions
- Achromatopsia
- Interventions
- Not listed
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Miami, Florida • Chicago, Illinois + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
- Conditions
- Pancreatic Cancer
- Interventions
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Pittsburgh, Pennsylvania • Seattle, Washington + 1 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin tartrate (ACP-103)
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 83
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1201
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Nivolumab, Cetuximab, Methotrexate, Docetaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 15
- States / cities
- Stanford, California • Tampa, Florida • Atlanta, Georgia + 11 more